Need for Considering New Trial Strategies
• On average only ¼ of cancer patients receiving an approved cancer drug regimen will gain a significant benefit from that treatment.
• Despite this lack of effectiveness of current therapies, they are considered "standards of care." • The ¾ of patients receiving these approved therapies with minimal benefit often suffer toxicities, and always have the consequence of delayed effective therapy.
• A significant component of this reality stems from the fact that many approved first line therapies were evaluated years to decades ago assuming a relative homogeneity in patient subtypes.
New Powerful Tools Can Detect Patient Subpopulations with Different Responses
• Recently developed powerful genomic and molecular tools can sub-classify tumors • Traditional biomarkers (e.g., for receptors-HER2) and emerging molecular markers now can allow identification of tumor subtypes from genome wide molecular analyses • These subpopulations may have different prognoses and responses to therapy
Post-Approval Non-Responder Studies
• A prospective study of a marketed drug, in which genomic data from biospecimens are used to identify biomarkers predictive of clinical outcomes.
• Objective is to identify biomarkers that reliably predict patients unlikely to benefit, and to use such data to support revision of the approved drug label and a change in standard of care.
• Many investigational drugs in clinical trials now are accompanied by molecular signatures that identify responder sub-populations. 
Opportunity to Identify Subpopulations of

Potential Explanations of Treatment Effect Seen in an Approved Drug
• Variability within clinical expectation of a homogeneous patient population
• Variability due to heterogeneity at molecular, genomic or genetic level that is either prognostic and/or predictive of therapy
Scientific Consideration of Post-Approval Non-Responder Study with Patient Initiated Study Participation
• A prospective study of a marketed drug with biospecimens prospectively collected following patient consents • Use genomic data to identify biomarkers that can reliably predict patients unlikely to benefit • Such data may be considered to support revision of the approved drug label and a change in standard of care • The sponsorship should be different from those industrysponsored trials with appropriate governance structure, in principle, with no financial and scientific conflict of interests • The study should be attentive to potential bias due to patient accrual, trial conduct and analysis interpretation if restrict label only in patient subset
Regulatory Considerations
Post-Marketing Study to Justify Label Revision
• Level of scientific rigor differs depending on study design 
Principles of the SAGE Non-Responder Project
• The treatment under investigation should have substantial response and non-response rates (>20 percent in either group).
• The disease must have clear, robust definitions of response and non-response that are clinically important. (A non-response biomarker should have the potential to change clinical practice.)
• Routine clinical management of the disease guarantees access to high quality tissue specimens.
• The non-response group should ideally be defined as patients refractory to treatment rather than those who respond then relapse early.
NSCLC Study Objectives
• Determine the feasibility of patient-initiated study enrollment • Yes, it is feasible. Patients and families can be highly motivated to accelerate research into discoveries.
• Paper reflects examples including LCA's own experience with the lung cancer community vis-à-vis "Give A Scan." • Give A Scan goal --to accelerate imaging research and software development so imaging can be a more accurate "quantitative biomarker" and thus expedite improvements in the early diagnosis and treatment of lung cancer.
Principles That Guided Give A Scan
• Database should be made available to all researchers.
• Patient privacy would be maintained at highest level possible.
• Patients should bear no cost.
• LCA would neither buy nor sell scans or data.
• LCA would not be directly involved in research.
• Patients would be advised upfront that research may lead to commercialization.
• Governance practices and policies observed -Advisory Board created.
Translate Experience to Non-Responder Project Using Patient-Initiated Study Participation for NSCLC
• Would patients be willing to donate specimens? Yes.
• Can principles be established to guide the study process? Yes.
• Are there additional challenges? Yes.
• Can they be overcome? Yes.
Patient Considerations and Challenges
• Timing will influence patients' receptivity to messages about study participation.
• At diagnosis --very difficult time to ask patients to consider this.
• Only way to acquire tumor tissue is biopsy or surgery.
• Most patients are not being biopsied as standard of care at this stage (rather being diagnosed by CT scans or PET/CT to assess tumor growth over time).
• Surgery is not an option in these patients.
• Overall challenging time to discuss study that has risk, might cause harm, and could potentially cost money.
How to Maximize the Opportunity to Collect Tumor Tissue
• Cover the cost of the biopsy and genetic assays for the tumor.
• Encourage CMS to cover new tools, such as Electromagnetic Navigation Bronchoscopy (ENB) that help facilitate biopsies and can reach peripheral tumors bronchoscopes cannot.
• Partner with researchers who are recruiting individuals at high risk for lung cancer for CT screening.
-Maximizing potential of diagnosing early stage operable lung cancer. -Patients already amendable to study participation. 
Comment About Lung Cancer Community
• The lung cancer community recognizes that very little is being done to sufficiently support them.
• They know that little if any research has been funded.
• They are angry.
• They want to do what they can to advance better outcomes -and if approached at the right time -with the right plan of engagement I believe they would participate. 
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